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ABSTRACT. Ultrasmall gold nanoclusters (Au NCs for short) show great potential in 
biomedical applications. Long-term biodistribution, retention, toxicity, and pharmacokinetics 
profiles are pre-requisites in their potential clinical applications. Here we systematically 
investigated the biodistribution, clearance, and toxicity of one widely-used Au NC species – 
glutathione-protected Au NCs or GSH-Au NCs, over a relatively long period of 90 days in 
mice. We observed that most of the Au NCs were cleared at 30 days post injection (p.i.) with 
a major accumulation in liver and kidney. However, it is surprising that an abnormal increase 
of Au amount in the heart, liver, spleen, lung, and testis was observed at 60 and 90 days p.i., 
indicating that the injected Au NCs formed a V-shaped time-dependent distribution profile in 
various organs. Further investigations revealed that Au NCs were steadily accumulating in the 
muscle in the first 30 days p.i., and the as-stored Au NCs gradually released into blood in 30–
90 days p.i., which induced a re-distribution and re-accumulation of Au NCs in all blood-rich 
organs. Further hematology and biochemistry studies showed that the re-accumulation of Au 
NCs still caused some liver toxicity at 30 days p.i. The muscle storage and subsequent release 
may give rise to the potential accumulation and toxicity risk of functional nanomaterials over 
long periods of time. 
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1. Introduction 
Gold nanomaterials have attracted exciting attention for medical applications, such as drug 
delivery, bioimaging, and cancer photothermal or radiation therapy.[1-7] In order for 
comprehensive clinical acceptance of these gold nanotechnology, the initial few steps require 
the determination of their pharmacokinetics and in vivo clearance.[8-14] Nanomaterials’ in vivo 
residence time and their eventual clearance from the circulatory system depends on a web of 
interwined parameters that are nanomaterial specific and tissue-organ distinctive.[10, 15-16] 
Larger sized Au nanoparticles (typically above 5 nm) tend to form aggregates in the 
biological settings due to the protein corona in physiological environments,[17-18] which may 
result in their preferential accumulation in liver and spleen possibly through nanoparticle 
induced endothelial leakiness (NanoEL) effect.[19] As highly vascularized organs receive most 
of the blood in body, circulating nanomaterials can be easily assimilated into these organs and 
if toxic, can cause organ damage.[17, 20-26] While surface PEGylation can prolong blood 
circulation time of Au nanomaterials, the as-modified Au nanomaterials may still be trapped 
in the reticulo-endothelial system (RES) because PEG is still an artificial synthetic molecule 
and perceived to be foreign by the immune system.[17, 27]  
Instead, we suggested that protecting Au nanomaterials with a naturally-occurring 
biomolecule, such as the ubiquitous tripeptide glutathione (GSH), might be a more natural and 
therefore a stealthy strategy to evade the RES surveillance and capture. This may overall 
further improve the stability and residence time of Au nanomaterials in the physiological 
environment to maximize their therapeutic benefits.[28] In addition, further decrease in the size 
of Au nanomaterials, especially to below 2 nm, might allow better biomolecule mimicry and 
interactions with cells and tissues and therefore enhance the stealth mode when under the RES 
surveillance. Summatively, we combined these two important concepts into a relatively new 
class of Au nanomaterials – GSH-protected ultrasmall Au nanoclusters (or GSH-Au NCs) and 
showed in several earlier studies promising biomedical applications.[29-31] These GSH-Au NCs 
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consist of an ultrasmall Au core with sizes below 2 nm enshroud in a self-assembled GSH 
layer.[32-33] Their biomedical applications have been recently demonstrated in many fields like 
bioimaging and cancer radiation therapy, showing excellent in vivo performance.[29-30] 
To further ascertain the clinical suitability of GSH-Au NCs, here we present a multi-
parametric in vivo study centered on residence times, clearance quantities and rates and 
toxicity determination of GSH-Au NCs over short- to middle-term (up to 90 days) time points. 
One recently reported GSH-Au NC – Au29-43(SG)27-37  NC was chosen in this study due to its 
excellent stability and high luminescence.[32] We observed that most of the Au NCs were 
cleared before 30 days post injection (p.i.) in mice, with a major accumulation in the liver and 
kidney. However, it is surprising that an abnormal resurgence of Au amount in major blood-
rich organs, such as heart, kidney, spleen, liver, lung, and testis was seen after 60 and 90 days 
p.i., which suggest that the injected Au NCs showed a V-shaped time-dependent 
dissemination-reaccumulation profile in mice over an extended period of time in vivo. Further 
investigations indicated that the muscle was the major contributor to this unexpected second 
resurgence. Our data clearly suggest that the in vivo distribution and clearance of GSH-Au 
NCs actually involved two stages instead of the earlier paradigm of a single stage release.[28, 
34] In the first stage (1-30 days), the blood circulation and the subsequent renal clearance of 
GSH-Au NCs made possible, a continuous decrease of Au NCs in those blood-rich organs; 
what was previously unknown was that there was also a simultaneous accumulation in the 
muscle most likely due to the NanoEL effect.[19] In the second stage (30-90 days), 
accumulated Au NCs in the muscle could no longer reside in the muscle and therefore started 
a continuous release back into the blood system, which then redistributed Au NCs to major 
blood-rich organs and led to an unexpected increase of Au amount in these organs after 30-90 
days p.i. 
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2. Results and Discussion 
Luminescent GSH-Au NCs were synthesized and purified according to our published 
procedures.[32] The as-prepared Au NCs were Au29-43(SG)27-37 as determined by the 
electrospray ionization (ESI) mass spectroscopy. A representative transmission electron 
microscopy (TEM) image (Figure 1a) showed that the GSH-Au NCs had a size below 2 nm. 
In addition, the as-prepared GSH-Au NCs showed intense orange emission (inset of Figure 1b, 
under UV illumination), with a distinct emission wavelength at ~610 nm (Figure 1b). The as-
prepared GSH-Au NCs had a good stability in solution. No obvious change in luminescence 
intensity was observed even after 90 days of storage at 4 oC (data not shown). We next 
monitored the luminescence properties of GSH-Au NCs in the blood plasma over the 
incubation time. As shown in Figure S1, no obvious change in luminescence intensity was 
observed in the first 2 h. We only observed a slight decrease of luminescence after 6 h of 
incubation, and >70% of luminescence intensity of GSH-Au NCs was conserved even after 24 
h of incubation. This data clearly suggest that the as-prepared GSH-Au NCs were stable in the 
blood plasma. While the slight decrease in the luminescence intensity of Au NCs could be due 
to the formation of protein corona on the surface of GSH-Au NCs, the luminescence 
dampening is reduced through our smart design of the poly-peptide coating on the Au NCs. 
High stability of GSH-Au NCs in blood is crucial for their further in vivo applications. This 
attractive feature also facilitates our in vivo biodistribution and clearance study. We chose 
C57 male mice as the animal model. The as-prepared GSH-Au NCs (3 mM, 0.2 mL) were 
injected intraperitoneally into the mice (8 mice per group), and the final dose of Au NCs in 
mice was ~5.9 mg/kg. The mice were sacrificed at 1, 7, 30, 60, and 90 days p.i., and the Au 
amount in major organs (n = 3) was determined by inductively coupled plasma mass 
spectrometry (ICP-MS). The biodistribution data were presented in Figure 2. The kidney was 
the dominant organ for Au NCs accumulation, followed by the liver and spleen. Heart, lung, 
and testis showed relatively low Au concentrations. The detailed biodistribution evolution 
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with time (1, 30, and 90 days p.i.) were illustrated as follows. After the first day p.i., the Au 
concentrations in kidney, liver, and spleen were 4702 (4% ID/g), 673 (0.6% ID/g), and 1231 
(1 % ID/g)) ng/g-tissue, respectively. After 30 days p.i., this measured Au concentration is 
509 (0.43% ID/g)) and 652 (0.55 % ID/g)) ng/g-tissue in kidney and liver, respectively; and 
then 1526 (1.3 % ID/g)) ng/g-tissue Au can be found in spleen. After 90 days p.i., the Au 
concentration in kidney is 975 (0.8 % ID/g)) ng/g, and 1956 (1.7 % ID/g)) and 1710 (1.4% 
ID/g)) ng/g in spleen and liver, respectively. The re-increase of Au concentrations in liver and 
spleen after 90 days p.i. is totally unexpected, and it forms the major focus of this study as the 
re-accumulation of Au NCs in some organs may directly correlate to their long-term clearance 
and toxicity issues. 
It is well demonstrated that renal clearance is one primary metabolism route for ultrasmall 
Au NCs with hydrodynamic diameters below 6 nm.[28, 34] Therefore, it is expected that kidney 
showed the highest Au concentration. On the other hand, since the hydrodynamic diameters of 
our Au NCs were <3 nm, and particles in this size regime may efficiently escape the RES 
absorption, a relatively low Au concentration was observed in the liver and spleen after 1 day 
p.i. The injected Au NCs in mice were slowly cleared via the renal clearance pathway, and the 
total Au amount in blood-rich organs reached the minimum after 30 days p.i. However, our 
data at 60 and 90 days p.i. suggest that the remaining Au NCs in the body could not be 
completely cleared during the period of 90 days. These Au NCs have induced an abnormal re-
accumulation in those blood-rich organs. The next question we may ask is what is/are the 
major contributor/s to this abnormal re-accumulation of Au NCs in the body.  
To better understand the re-accumulation process, we investigated the time-dependent 
biodistribution of Au NCs in all major organs. As shown in Figure 3, the determined Au 
amount in liver was increased from 593 to 2224 ng from 1 to 90 days p.i. While kidney is the 
main organ for foreign particles clearance from the blood, and it is totally expected to observe 
a drastic decrease in the Au amount from 1081 ng (1 day) to 269 ng (90 days), there was still 
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an unexpected mid term increase resulting in a “V-shape” profile (Figure 3). These “V-
shapes” were also observed in the profiles of the lung, heart, and testis with the increase of 
clearance time – a continuous decrease of Au contents from 1 to 30 days and a continuous or 
semi-continuous increase from 30 to 90 days. The revived increase of Au contents in the 
blood-rich organs after 30 days p.i. was unexpected. This data also suggests a biphasic 
decrease-increase pharmacokinetics profile of Au NCs in mice, in stark contrast to the well 
known and reported mono-phasic decay pharmacokinetics of nanomaterials.[10, 35-37] Therefore, 
we surmise that other organs that were not characterized or missed in previous studies might 
be storing nanomaterials over a long period. This organ may first act as a repository for Au 
NCs in the first phase, and subsequently serves as a dispensary for the stored Au NCs to other 
organs, resulting in the re-accumulations of Au NCs in other organs.  
We further analyzed the possible reasons for this decrease-increase trend in biodistribution. 
From the perspective of mass balance, some fluctuations in biodistribution of Au NCs are 
tolerable in major organs.[28, 36, 38] However, the Au contents in the liver increased two fold to 
>1500 ng, while the kidney had only about 850 ng decrease of Au NCs, and this is not 
sufficient to account for the above deficit. More importantly, the kidney is a dominant organ 
to clear Au NCs in the body, and thus the Au amount decrease in kidney is not attributed 
solely to the re-distribution between the above mentioned organs. The second possible reason 
is related to hepato-enteric circulation. It is well known that the hepato-enteric circulation 
may lead to the storage of foreign particles in the liver and other intestinal organs, which will 
be released at a later stage.[39] However, if the liver storage is the major contributor to our 
observations, the Au amount in the liver may undergo a remarkable decrease at some stage, 
which was inconsistent with the observations in our system – instead the Au amount in the 
liver increased. Since muscle mass accounts for about 40-60% of the body weight of mice, 
any small Au amount variation in muscle may lead to an obvious change in other organs. 
Thus, we hypothesized that muscle might have been the source of the second phase release.  
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To prove our hypothesis, we measured the time-dependent Au amount in muscle by ICP-
MS. As shown in Figure 4a, the Au concentration was 2524 ng/g in muscle after 1 day p.i. 
This value increased to 5588 ng/g after 30 days p.i. A remarkable drop of this value to 187 
ng/g was observed in muscle after 90 days p.i. This data provided a direct experimental 
evidence for our hypothesis, where muscle is the major contributor to the re-accumulation of 
Au NCs in other organs after 30 days p.i. According to our analysis, the in vivo 
pharmacokinetics of Au NCs in mice could be illustrated in Figure 4b, which involved two 
stages. The first stage (1-30 days) was the renal clearance and the muscle storage of Au NCs. 
In this stage, the injected Au NCs in mice were metabolized by kidney and other organs, 
leading to a continuous decrease of Au concentration in major organs from 1 to 30 days p.i. 
Meanwhile, possibly due to strong nanoparticle induced endothelial leakiness or NanoEL 
effect,[19] the Au concentration gradually increased in the muscle, leading to a continuous 
storage of Au NCs in muscle. The second stage (30-90 days) was the muscle release and 
redistribution of Au NCs in the blood-rich organs. In this stage, Au NCs stored in the muscle 
were slowly released and re-entered into the blood circulation. The circulation in the blood 
therefore redistributed the Au NCs to those blood-rich organs, inducing an abnormal increase 
of Au NCs in those organs.  
The re-accumulation process is interesting, but it could also be risky since for the first time, 
we showed that there is a longer than the expected residence time of injected nanomaterials in 
body due to a reflux of nanomaterials from muscle back into the major organs. We then 
evaluated the toxicological response of Au NCs in the period of 90 days. The dose of Au NCs 
was set at 5.9 mg/kg, and the body weight, immune response, hematology, and biochemistry 
of mice were systematically investigated at 1, 7, 30, 60, and 90 days p.i. As shown in Figure 
S2, in the period of 90 days, the treatment with Au NCs in mice did not induce obvious body 
weight loss, and spleen and thymus toxicity indices. In addition, we used some gold-standard 
clinical hematotoxicity markers for the toxicity analysis of injected Au NCs in mice, 
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including the white blood cell (WBC), red blood cell (RBC), hematocrit (HCT), mean 
corpuscular volume (MCV), hemoglobin (HGB), platelet (PLT), mean corpuscular 
hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC). The 
hematology data were presented in Figure 5, where no obvious difference in two common 
indicators (RBC and WBC) was observed in the Au NCs-treated mice compared to those of 
untreated mice. However, a slight change in MCV, MCH, MCHC, and PLT was observed 
after 30 days p.i., but these data were recovered after 90 days p.i. This observation was 
however consistent with the biodistribution data. Although GSH provided a biocompatible 
layer for the as-prepared GSH-Au NCs, the re-accumulation of them may still induce 
potential toxicological responses. Moreover, we also examined the standard biochemistry and 
pathological changes of organs by using immunohistochemistry. As shown in Figure 6 and 
Figure 7, no obvious organ damages were observed in liver, spleen, and kidney in the period 
of 90 days after the injection of Au NCs.  
The previous studies mostly correlated the potential toxicity of functional nanomaterials to 
their clearance in body.[13, 40] However, the actual in vivo pharmacokinetics of functional 
nanomaterials could be even more complicated. The data presented in this study clearly 
indicated that most of the ultrasmall Au NCs can be efficiently cleared by kidney, but the 
strong nanoEL effect could facilitate the penetration of Au NCs into the relatively poor 
vascularized tissues, resulting in an appreciable storage of Au NCs in muscle. The as-stored 
Au NCs can be slowly released into the blood, and the blood circulation may redistribute 
them to those blood vessels-rich organs. Therefore, the present work suggests the potential 
adverse risk due to this previously unobserved second wave of accumulation-release of small-
sized metal NCs and even other nanomaterials of known toxicities.[41, 42] This new paradigm 
should be taken into account in future materials design, especially those meant for medical 
applications. 
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3. Conclusion 
In summary, we investigated the long-term (90 days) in vivo toxicity and clearance of one 
commonly-used GSH-Au NCs. It was found that most of Au NCs can be metabolized by renal 
clearance. Within a typical short test period (30 days), as expected, Au NCs gradually 
decreased in the highly vascularized organs, such as heart, liver, spleen, and lung. However, 
at a longer time period (after 30 days), the Au amount in the organs started to climb again. 
Further investigations confirmed that the muscle behaves as a Au NC sink for the initial 30 
days, but subsequently initiates another wave of redistribution to the other organs. The 
subsequent toxicity test showed that the re-accumulation of Au NCs induced a slight toxicity 
response at the present dose level. Present work clearly suggests that muscle can store and 
release ultrasmall nanomaterials, which may cause reaccumulation of functional 
nanomaterials and result in potential toxicity.  
 
4. Experimental Section 
Materials and synthesis: The orange-emitting Au29-43(SG)27-37 NCs were synthesized using 
a previously reported method. Briefly, freshly prepared aqueous solutions of HAuCl4 (20 mM, 
0.50 mL) and GSH (100 mM, 0.15 mL) were mixed with 4.35 mL of ultrapure water at 25 °C. 
The reaction mixture was heated to 70 °C under stirring (500 rpm) for 24 h. The resultant 
solution of Au NCs is light yellow under room light and shows strong orange emission under 
UV (e.g., 365 nm) irradiation. The Au NCs were purified using ultrafiltration [with molecular 
weight cut off (MWCO) of 3 kDa]. The raw product and purified Au NC solution could be 
stored at 4 °C for 6 months with negligible changes in their optical properties. 
Materials characterization: Transmission electron microscopy (TEM) analysis was 
conducted with a JEOL JEM-2100F microscope operated at 200 kV. The zeta-potential 
analysis and HD size of the Au NCs was determined with the NanoZS Zetasizer particle 
analyzer (Malvern). Data were acquired in the phase analysis light scattering mode at 25 °C, 
and sample solutions were prepared by diluting Au NCs into 10 mM PBS solution (pH 7.0). 
The UV-vis absorption spectra were recorded on a UV-1800 spectrophotometer (Shimadzu). 
The photoluminescence (PL) spectra were measured by a fluorescence spectrophotometer 
(F4600, Hitachi). Stability of Au NCs was evaluated using fluorescence spectra. The Au NCs 
(3 mM, 05 mL) were diluted one time in human blood plasma, and fluorescence spectra were 
measured at the time points of 0.5, 2, 6, 12, and 24 hours using a fluorescence 
spectrophotometer in a 5 mL glass cuvette. 
Animal injection and sample collection: Animals were purchased, maintained, and handled 
with protocols approved by the Institute of Radiation Medicine, Chinese Academy of Medical 
Sciences (IRM, CAMS). 80 Male C57 mice at 11 weeks of age were obtained from IRM 
laboratories and were housed by 2 mice per cage in a 12 h/12 h light/dark cycle with food and 
water ad libitum. Mice were randomly divided into ten groups (eight mice in each group): 1 
day control, 1 day treated, 7 days control, 7 days treated, 30 days control, 30 days treated, 60 
days control, 60 days treated, and 90 days control, 90 days treated mice, respectively. The Au 
NCs (3 mM, 200 μL) was used for the animal experiment using intraperitoneal injection. The 
concentration was 5.9 mg/kg in each mouse. At every day time point after injection, animals 
were weighed and assessed for behavioral changes. After 1, 7, 30, and 90 days treatment, all 
mice were sacrificed, and blood and organs were collected for biochemistry and pathological 
studies. Mice were sacrificed using isoflurane anesthetic and angiocatheter exsanguination 
with PBS. One mouse from each group was fixed with 10% buffered formalin following 
phosphate-buffered saline exsanguination. During necropsy, liver, kidneys, spleen, heart, lung, 
testis, brain, bladder, and thymus were collected and weighed. To explicitly examine the 
grade of changes caused by malities, spleen and thymus indexes ( ) were used: xS
Sx  Weight of experimental organ (mg)Weight of experimental animal (g)  
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Hematology, biochemistry, and pathology: Using a standard saphenous vein blood 
collection technique, blood was drawn for hematology analysis (potassium EDTA collection 
tube). The analysis of standard hematological and biochemical examination was performed. 
For blood analysis, 1 mL of blood was collected from mice and separated by centrifugation 
into cellular and plasma fractions. Mice were sacrificed by isoflurane anesthetic and angio 
catheter exsanguinations, and major organs from those mice were harvested, fixed in 10% 
neutral buffered formalin, processed routinely into paraffin, stained with H&E and pathology 
were examined by a digital microscope. 
Biodistribution: The organs and original solutions from the Au NCs-treated mice (3 
samples per group) were digested by using a microwave system CEM Mars 5 (CEM, Kamp 
Lintfort, Germany). The Au concentration was measured with an ICP-MS (Agilent 7500 CE, 
Agilent Technologies, Waldbronn, Germany).  
Statistical analyses: All data presented in this study are the average ± SD of the experiments 
repeated three or more times. The paired Student's t-test was used for statistical analysis. 
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Figures and Figures Captions 
 
    
 
Figure 1. (a) TEM image and (b) UV–vis absorption (solid blue line), photoemission (solid 
red line, λex = 365 nm), and photoexcitation (dotted red line, λem = 610 nm) spectra of the as-
prepared GSH-Au NCs. (Inset) Digital photo of the aqueous solution of the GSH-Au NCs 
under (1) visible and (2) UV light. 
 
 
Figure 2. Biodistribution of Au NCs determined by ICP-MS at 1, 7, 30, 60, and 90 days p.i. 
15 
 
 
Figure 3. Au amount in heart, liver, spleen, lung, kidney, and testis from the mice treated by 
Au NCs. The data were collected at the different time points of 1, 7, 30, 60, and 90 days p.i. 
 
Figure 4. (a) Au concentration in muscle from mice treated with Au NCs, and (b) Schematic 
illustration of time-dependent clearance of GSH-Au NCs injected in mice. 
16 
 
 Figure 5. Hematology data of the mice treated with the Au NCs. The data were collected at 
different time points of 1, 7, 30, 60, and 90 days after intraperitoneal injection (5.9 mg/kg). 
The results show the red blood cells (RBC), white blood cells (WBC), platelets (PLT), mean 
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean 
corpuscular volume (MCV), hemoglobin (HGB), and hematocrit (HCT). The data were 
analyzed by Student’s t-test and * indicates p < 0.05. 
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 Figure 6. Blood biochemistry analysis of the mice treated with the Au NCs at different time 
points of 1, 7, 30, 60, and 90 days. The results show the mean and standard deviation of 
aminotransferase (ALT), aminotransferase (AST), total protein (TP), albumin (ALB), blood 
urea nitrogen (BUN), creatinine (CREA), globulin (GOLB), and total bilirubin (TBIL). The 
data were analyzed by Student’s t-test and * indicates p < 0.05. 
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 Figure 7. Pathological data from the liver, spleen, and kidney of the mice treated with the Au 
NCs. The data were collected at different time points of 1, 30, and 90 days after injecting 5.9 
mg/kg Au NCs.  
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GSH-protected ultrasmall Au nanoparticles (1-2 nm) which from a size perspective 
would normally be cleared expeditiously from the internal organs within a few days post 
injection, can actually remain and accumulate to very high concentrations for a much 
longer time (> 60 days) in the muscle versus other internal organs. Subsequently, this 
accumulation in the muscle starts to release the nanoparticles back into the vascular 
circulation and initiates another phase of nanoparticle biodistribution.   
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Figure S1. Time-dependent fluorescence of the GSH-Au NCs.  
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Figure S2. (a) Body weight, (b) thymus, and (c) spleen index of the mice treated with the Au 
NCs. 
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